What's about Italian hemp: crisis media relations for Italian league of hemp entrepreneurs

Judiciary and community news, economics and politics, circular and sustainable chain value

section: clients

24-09-2025
categories: Corporate, Non profit,

» archive clients

What's about Italian hemp: crisis media relations for Italian league of hemp entrepreneurs

Judiciary and community news, economics and politics, circular and sustainable chain value


Canapa Sativa Italia (CSI) is the national association that unites all operators in the hemp sector: from agriculture to processing, research, and distribution throughout the country.

Established on social media in 2014 by founding a large group of many operators from all sectors of the supply chain, it was formalized as an association four years later, on July 15, 2018, becoming a fully representative body of the sector: from growers to traders, from processors to analytical specialists, and from legal technicians and professionals in related activities.
Today, Canapa Sativa Italia boasts an ever-growing number of organizations committed to the cooperation and development of Italian hemp.

As of September 30, 2025, 380 companies are members, divided into 175 agricultural companies, 185 commercial companies, 5 research companies, and 15 processing companies.
The association represents the new supply chains and, through ongoing dialogue among all stakeholders, ensures the constant and timely sharing of the most relevant information for the hemp sector in Italy.

The Board of Directors meets weekly and organizes conference calls open to members. Members engage in dedicated groups and have access to counseling to address potential legal and law enforcement challenges. Members enjoy various benefits, including legal insurance, legal assistance from experienced lawyers, and discounts on various services, including laboratory testing, shipping, and discounted participation in industry trade fairs. Informational webinars are also organized for all industry stakeholders, along with handbooks on best practices for use in the field and in the store.

The most widely followed association of hemp entrepreneurs participates in major Italian trade fairs and constantly coordinates with other European industry associations, with whom it engages in frequent discussions to develop and defend the sector. This is particularly true regarding the promotion of local and professional craftsmanship, as well as the exercise of the right to investigate violations of rights and even seek compensation for economic damages resulting from regulations that violate relevant national and European legislation.

Is industrial hemp legal in Italy today?

Yes. Law 242/2016 states: Cannabis sativa L. can be grown from varieties registered in the EU catalog and used for industrial, ornamental/floricultural, textile, and food purposes according to European regulations. In the field, the threshold of 0.6% (maximum permitted THC/tetrahydrocannabinol percentage) applies.

Yes, hemp is legal. Despite Article 18 of Legislative Decree no. 48/2025, converted into Law No. 80 of June 9, 2025 (the so-called Security Decree), refers inflorescences to Law No. 309/90, and the same criminal law states that a crime cannot be committed without actual harmfulness. Industry regulations are applied to finished products, and if anyone attempts to impose absolute bans on inflorescences, leaves, and derivatives, the guiding principle remains that of actual harmfulness: a product is considered "drug-inducing" only when it can produce a narcotic effect, altering the actual psychophysical state, something that hemp and the derivatives sold by the industry are incapable of doing. Since they are not narcotics, the derivatives sold by industry operators also comply with Law No. 309/90.

What we are doing in the courts is simple: make this clear, in black and white, so that legal purposes and the absence of a narcotic effect are no longer the subject of "creatively prohibitionist" interpretations.

And the Trento decision? Did we win or lose?

A judiciary setting ruled in Trento court (Trentino Alto Adige region) asked for a precautionary suspension of Article 18 that was rejected because the judges confirmed CSI interpretation, namely that nothing has changed since the Security Decree. In his reasoning, the judge precisely echoed CSI interpretation: what matters is the lawful uses of Law 242/2016 and, above all, the absence of a concrete intoxicating effect. This recent ruling from Trento is a valuable assist, bringing this language to the final decision, scheduled for December 2025. The key now is to make it a substantive and replicable ruling, so that controls can stop relying on fanciful and overly broad interpretations of Article 18.

Cannabidiol

It is one of the 142 phytocannabinoids identified in Cannabis Sativa L. plants. It is found throughout the plant. Cannabis Sativa L.—technically defined as Industrial Hemp and, in an inappropriate journalistic synthesis, cannabis light—is legal in Italy thanks to Law 242/16 and its intrinsic lack of intoxicating properties.
CBD specifically has no intoxicating effect and is not addictive, as proven by countless studies.

It is also found in other botanical species, such as hop leaves.

Cannabidiol is approved by drug agencies for use in anticonvulsant and antiepileptic treatments and as an adjuvant in the treatment of multiple sclerosis.

In the form of a dietary supplement, it is a powerful muscle relaxant and offers significant, low-cost benefits for anxiety, insomnia, chronic pain, neurodegenerative diseases, or as an adjuvant during opioid detoxification and other chronic addictions.

The fact that CBD does not have the same psychoactive properties as THC, the main psychotropic agent in cannabis, has also been recognized by international regulatory bodies and established by the World Health Organization. On November 19, 2020, with ruling 141, the European Court of Justice affirmed that CBD extracted from the cannabis plant should not be considered a drug under the 1961 United Nations Single Convention on Narcotic Drugs. The Single Convention itself was revised by the UN on December 2, 2020 based on WHO recommendations, marking a historic turning point in the recognized therapeutic use of the plant.

Until February 4, CBD was authorized as a cosmetic ingredient only in synthetic form, but on February 4, 2021, the Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs (DG Grow) of the European Commission (EC) changed this position and added cannabidiol (CBD) extracted from the plant to the CosIng catalog for cosmetics.

The gradual and partial legalization of cannabis at the beginning of the 21st century led to extensive research into the potential human uses of CBD. Since 2017, when the WHO declared CBD no longer a controlled substance, clinical research on CBD has increasingly included studies related to anxiety, cognition, movement disorders, pain, and cancer.

Low-THC cannabis sativa, legal in Italy thanks to Law 242/16 and due to its inability to produce narcotic effects, in addition to being registered as certified varieties authorized for cultivation in Europe, must contain a maximum THC content of 0.6 mg, according to Italian law.

Industrial hemp cultivation, like other plants whose varieties are registered in the agricultural registers of various European countries, is eligible for CAP (Common Agricultural Policy) agricultural funds, whether grown in open fields or indoors.

Is CBD a drug? What changes with the 2024 Ministry of Health decrees?

No, CBD is not a drug. The 2024 decrees attempted to classify and therefore classify as narcotic drugs oral compositions containing CBD extracted from the plant, not "CBD itself." These decrees attempted to bypass both European cosmetics regulations (where CBD extracted from the plant, as we said, is already included in CosIng) and the novel food pathway for food.
The first version of this decree was suspended as a precautionary measure, then the Ministry rewrote the text drawing on ISS/CSS opinions, and in the first instance a Regional Administrative Court rejected our appeal, but without truly addressing the scientific counterarguments and without consulting an expert witness, bowing to an exaggerated precautionary principle.
We therefore appealed to the Council of State with regulatory and toxicological reports, including work with the company ChemSafe (Regulatory Toxicology Agency) and technical contributions from experts Professors Falasca and Ciallella: the evidence shows that CBD, as such, is neither narcotic nor addictive, and that an umbrella ban on oral forms, without proportionate parameters, conflicts with EU law and the reality of use.

In the meantime, let's reiterate a practical point: the decree does not magically transform every CBD-based product into a "narcotic"; it affects a specific form of administration. Yet, some continue to seize products, confusing composition and substance: then seizures and dismissals follow, but in the meantime, companies and taxpayers foot the bill.

Why isn't it a Schedule B medicine? https://drive.google.com/file/d/1nW10AJuVOUFuUsBpfMgkhdrtdsZ4TL7h/view?usp=sharing


Ministerial Hemp Supply Chain Committee
(formerly MIPAAF, now MASAF, Ministry of Agriculture and Food Sovereignty)

With great commitment, Canapa Sativa Italia succeeded in becoming the institutional representative of the sector, obtaining a seat at the ministerial supply chain committee at the then MIPAAF, established by former Agriculture Minister Bellanova.

The committee was formed in 2020 and first established in 2021. It was supposed to complete its work and publish a sector plan by 2024, but to date it has been interrupted by the change of government and, unfortunately, has not yet presented the Sector Plan on which the work, albeit with great difficulty, had been carried out and completed.

Completed. Since then, the meeting and request for discussion of the matter at the technical table has become a common request not only among the industry associations that were part of it but also among major trade organizations such as Confagricoltura, Coldiretti, Cia, Copagri, CNA, and many others, which have continually requested its meeting. CREA and the universities involved and participating in the work have also produced many useful inputs for the development of this sector, contributions that have consequently been frustrated by the lack of meetings and positions.

To date, no official leaders have been appointed, despite our association continuing to actively collaborate with MASAF whenever it is convened. But the Plan, if it exists, is sitting on the desk awaiting approval. The work done with the institutions could indeed lead to clarification on the true scope of the new Article 18, invoking the Supreme Court ruling that does not prohibit the marketing of hemp derivatives when they lack narcotic efficacy according to the principle of harmfulness.

We await clarifications that can bring clarity on this front. It's likely that ultimately, we'll have to admit that Article 18 has been misinterpreted, further involving prosecutors with alarmism. We expect the government to provide an authentic interpretation that truly explains the scope of Article 18 and that we can effectively reopen the entire dialogue, having overcome and clarified this point: the government will never legalize any drug, and any product theoretically derived from hemp with intoxicating effects must be considered banned from now and for the future. At the same time, the marketing of non-intoxicating hemp must be recognized as non-punishable. At that point, we hope, the need will arise again to complete and integrate the work of the roundtable, giving a new future to this sector.

Low-THC industrial hemp is legal, but in recent years, four decrees have attempted to ban its cultivation, use, and export: a map of legal actions and appeals won by CSI.

Cannabidiol and low-THC industrial hemp, likely for economic reasons disguised as public health precautions, have frequently been targeted over the past five years. CSI members have therefore funded four national and international lawsuits and numerous political and press campaigns due to multiple violations of the law, and have achieved numerous successes.

The Italian government frequently reintroduces legislation or decrees that conflict with industry regulations and the cornerstones of EU law, causing unjustified and severe restrictions on business freedom.

The financial commitment required to Canapa Sativa Italia members and to all companies in the sector to meet all these contested measures—which result in unwarranted seizures of field and warehouse assets—is significant. 
Each measure entails years of uncertainty, the commissioning of new studies, the hearing of expert opinions, and numerous court cases (not to mention appeals filed by the losing parties), resulting in costs—difficult to quantify—ranging from €5,000 just for filing the appeal to €100,000. This unjustified business cost falls on young entrepreneurs in the sector, already strained by the difficult economic climate caused precisely by the uncertain climate and the constant issuing of decrees, often urgent, on matters already regulated by national law. A waste of public resources that also impacts the community.

2020, 'Speranza' Decree, suspended, then approved by Health Minister Schillaci after

The former Minister of Health, Hon. Speranza (Article 1, formerly Democratic Party), with the infamous "Speranza Decree" issued in the midst of the pandemic (2020), attempted to "give away" CBD exclusively to the pharmaceutical sector, but following vigorous protests, the decree was suspended. It was never repealed and, as we will see below, was subsequently reinstated.

2021, "Patuanelli Decree" (Officinals): what it provided, why we stopped it, where we are now
The story begins in June 2021, when the then Minister of Agriculture, Stefano Patuanelli, submitted to the Unified Conference the draft decree on medicinal plants provided for by Legislative Decree 75/2018. In the version that later became Ministerial Decree of 21 January 2022, a last-minute twist was inserted that lit the fuse: industrial hemp is effectively restricted to seed production only, while leaves and inflorescences are "parked" in the Consolidated Law on Narcotics (Presidential Decree 309/90), with the practical consequence of prohibiting cultivation and first-stage processing unless authorised by the pharmaceutical industry. Translated: a regular agricultural sector, recognised by Law 242/2016, suddenly finds itself with an operational block on parts of the plant that, if they had no narcotic effect, would have nothing to do with it.

CSI, along with a broad range of associations, immediately challenged the decree: it's not just a methodological issue, it's a matter of disproportion and conflict with Law 242/2016. An administrative act cannot eliminate what the law recognizes as industrial uses; and above all, legality cannot depend on which part of the plant is considered; the specific harmfulness must be established (the presence or absence of a narcotic effect).

The turning point came in February 2023: the Lazio Regional Administrative Court (Section V), with rulings no. 2613/2023 and no. 2616/2023, upheld the appeals and annulled the sections of the Ministerial Decree that closed the door on leaves and inflorescences. The administrative judges clearly stated what we've been repeating for years: a part of the plant isn't banned as such; the actual narcotic effect is assessed. Period.

The Ministries are not stopping and are appealing. Thus, we have reached the public hearing on October 2, 2025, before the Council of State, where we have filed briefs and technical dossiers. The hearing went well, and we await the ruling, with excellent prospects of confirmation.
Why is this step so important? Because this is a landmark case that could end a period of misunderstanding: if the TAR is upheld, the Ministerial Decree of January 21, 2022, can no longer be used to generally ban the leaves and inflorescences of industrial hemp; agriculture and primary processing will fall firmly within the scope of Law 242/2016; controls will once again focus on traceability and harmfulness, not merely the morphology of the plant; and the Italian system will realign with the EU principles of free circulation and proportionality.

The possible outcomes in the Council of State are all beneficial: a confirmation of the suspension of forced hemp use in the Consolidated Law on Medicinal Products would consolidate the precedent, while a referral to the EU Court of Justice or the Constitutional Court could provide definitive supranational clarification that finally settles the matter once and for all. Even a well-reasoned rejection reiterating that the activity is legitimate without a narcotic effect could become operational instructions for offices and municipalities. In any case, this legal battle has the potential to become the first definitive precedent that secures the supply chain for leaves and inflorescences and dismantles, at its root, the idea that a return to absolute bans based on specific parts of the plant by decree can be achieved.

On November 11, 2025, the Council of State issued an order referring the matter to the EU Court of Justice.

What the Council of State says
• EU: no distinction between parts of the plant.

The Lazio Regional Administrative Court (Regional Administrative Court, Ruling 2616/2023) is cited for the principle that EU legislation, in permitting the cultivation of approved varieties, "makes no distinction between the various parts of the plant."
• Questions to the CJEU on the use and sale of "light" inflorescences.
The CdS asks the Court whether European agricultural rules (CAP and TFEU) preclude national legislation that prohibits the cultivation/use of leaves and inflorescences and their derivatives (CBD) from approved varieties within THC limits.
• Internal market: "unjustifiable" restrictions.
The Italian restrictions on leaves/inflorescences and derivatives "give rise" to import/export restrictions that are unjustifiable for health/public order reasons, given that THC is "extremely low"; hence, possible non-compliance with Articles 34–36 TFEU.
• CBD legal in other Member States: a weighty comparison.
Cannabidiol production "appears to be legal in other Member States," impacting Italian restrictions on intra-EU trade.
• Scenario indicated: non-application of incompatible domestic law.
It is "possible" that Law 242/2016 (read with Presidential Decree 309/90) "must be considered in conflict with European regulations and should therefore be disapplied."
• Amendment 2025: irrationality of "inflorescences only."
The 2025 reform limited the scope of Presidential Decree 309/90 to "inflorescences only," restoring the legality of leaves and seeds (permitted varieties, 0.2% with a 0.6% tolerance).
The amendment has not diminished the interest of industry operators in appealing, as Law 242/2016 continues to prohibit the use of inflorescences and related derivatives, even from varieties permitted within the CAP limits.

The appeal was handled by Legance law firm with the support of Italian attorney Giacomo Bulleri, who states: "I believe this ordinance has fully addressed the critical issues that have emerged over the last 10 years and which continue to create confusion surrounding hemp. The issue is actually very simple: the hemp plant in its entirety (derived from certified varieties with a low THC content) is an agricultural product, to which the law on narcotics cannot apply. I hope that the judgment before the European Court will be an opportunity to introduce a necessary distinction.

This will definitively change our approach to the issue, that is, stop criminalizing a plant and focus on the quality and safety of the resulting products, allowing us to develop the full potential of the supply chain.

Therefore, this is excellent news because:
1. EU alignment: if the EU does not distinguish between parts of the plant, a selective ban on inflorescences is vulnerable to discrimination and disproportion.
2. Free movement: the Council of State explicitly speaks of unjustifiable restrictions and possible non-compliance with the TFEU: this is the basis for waiving internal bans.
3. European convergence: the recognition that CBD is legal elsewhere in the EU pushes towards harmonization along the supply chain and against isolated national barriers.
4. Updated framework: the same 2025 amendment, which protects leaves and seeds but only affects inflorescences, highlights the unreasonableness of the ban and facilitates its proportionality review.

Mattia Cusani, CSI President:
"This is a step Decisive: the Council of State captures the Italian anomaly and asks the CJEU whether it is truly possible to target only inflorescences when the EU does not distinguish between plant parts and THC is minimal. For businesses and retailers, this means a concrete prospect of legal peace of mind and protection of the supply chain, in compliance with European regulations.

"The Court clarifies that the interest remains current: the ban on inflorescences is still written into Law 242/2016 as amended, therefore the EU issue must be resolved and will also concern the new Article 18 of the Security Decree. In the meantime, national judges already have the tools to disapply rules incompatible with the TFEU." Judge Rules

2024 Repeal of the Speranza Decree on CBD

In 2024, the current Minister of Health reapproved the Speranza Decree, which sought to include oral CBD oils in the list of drugs at risk of abuse, seeking to once again limit their sale to pharmacies with a non-repeatable medical prescription. This decree would have severely limited the CBD sector, jeopardizing various industrial sectors such as herbal medicine, cosmetics, phytotherapy, and food supplements. Numerous scientific studies, including those by the World Health Organization (WHO), as mentioned, have demonstrated that CBD does not pose a risk of abuse or addiction. CBD does not have psychotropic effects.

The decree was initially promulgated without the in-depth analysis and scientific basis to justify the listing of CBD among narcotics; therefore, together with other industry associations, we filed a new appeal. On September 11, 2024, the Regional Administrative Court (TAR) of Lazio granted the appeal. A precautionary motion filed by the National Association of Hemp Sativa Italy and other associations suspends the Ministry of Health's decree of June 27, 2024.

However, the government withdraws that decree and reissues an identical one, remedying the formal lack of investigation thanks to new technical opinions submitted by the ISS and CSS. These opinions, however, contain clearly specious studies and significant scientific gaps. For this reason, the associations produced two expert reports: one by Professor Falasca (a chemist and pharmacologist) and one by Professor Cialella (a forensic medicine expert), which rebut point by point the recent opinions of the ISS and CSS, bodies belonging to the same Ministry of Health.

Despite this, in a move of interpretation that we believe is incorrect on the part of the first-instance judge, the appeal was dismissed with a clear lack of investigation because the counterarguments presented to the opinions were not answered impartially, and the ruling was made without first conducting an official technical investigation to delve deeper into the scientific aspects. Therefore, relying solely on the opinions of the ISS and CSS and on an exaggerated precautionary principle.

CSI and other trade associations are therefore requesting an appeal of the TAR ruling to the Council of State, with first-instance lawyers Simonetti and Miglio, and expanding their legal team to include former judge and President of the Council of State Sergio Santoro, the Prestige law firm, and lawyers Libutti and Bulleri. The legal team is also supported by a toxicological assessment by ChemSafe, a regulatory toxicology institute. The Council of State is expected to see a victory for the sector, given the opposing party's lack of investigation and the clear violation of national and, above all, European legislation.

Article 18 of the Security Bill (Legislative Decree 48/2025, converted into Law No. 80 of June 9, 2025) and the complaint to the European Commission, which was implemented.

In the so-called Security Bill, a bill historically supported by the Lega Nord and the FDI (Italian Federation of Italian Workers' Party), the government inserted the amendment 13.06 which later became Article 18 of the so-called "security decree" which, trying to recall the ruling of the SeThe 2019 Supreme Court of Cassation's United Nations Decision on cannabis reiterates the existing ban, but does so without the necessary wording that the Supreme Court had inserted, the wording that explicitly excluded criminal liability for the production, sale, and marketing of cannabis when it lacks narcotic effects, thus requiring the necessary reference to the principle of harmfulness.

Amendment 13.6 (Measures concerning hemp inflorescences and products derived therefrom) was approved in the dead of night between July 31 and August 1, 2024, in the joint Constitutional Affairs and Justice Committees of the Chamber of Deputies. This amendment would appear to introduce a crackdown on light cannabis inflorescences, which could not be cultivated, exported, or processed, omitting the mandatory wording in the legislation that clarified that such a ban could only be applied to derivatives that were specifically narcotic. The Security Bill was approved by the Chamber of Deputies after lengthy deliberations, but without waiting for the end of the debate and the final vote in the Senate, it was replaced with an emergency decree (later converted into law) that became known as the Security Decree. Becoming law overnight in April 2025, precisely during the days in which the largest Italian hemp trade fair, the Indica Sativa Trade, was taking place, this decree-law affects the stability of our sector, but above all, This would appear to call into question some fundamental rights of a constitutional state.

The Office of the Supreme Court of Cassation's Criminal Law Index Office immediately intervened to support the cannabis operators in its Report No. 33 of June 2025, clarifying that to avoid clear unconstitutionality and a clear conflict with European law, Article 18 can only be interpreted as a mere declaratory ruling of the 2019 Supreme Court ruling. To be constitutional and in line with EU law, Article 18, according to the Supreme Court's Index, can only be interpreted as a ban on what was previously prohibited; therefore, it can only ban narcotics and cannot ban the non-narcotic hemp with low THC levels and containing CBD that has been marketed up to that time and today.

As soon as the association learned of Amendment 13.06, it filed a complaint with the European Union against the ambiguity of Article 18 of the Security Bill, along with many other operators in the sector, explaining that this provision does not It can prohibit the cultivation, trade, processing, and transportation of industrial hemp with THC levels below legal limits (erroneously referred to as "cannabis light"), but can only prohibit narcotic substances. Furthermore, the decree was not notified to the TRIS (Technical Regulation Information System), the European Union system that requires member states to notify new technical regulations that restrict free trade before their adoption. This omission represents a further violation of EU procedures, which aim to ensure transparency and consistency of regulations among member states.

By notifying the European Commission of a potential violation of European Union regulations on free competition and the movement of goods, resulting from Amendment 13.6 proposed to the Security Bill, CSI is calling on the European Commission to issue a detailed opinion as required by Directive (EU) 2015/1535. The Commission has received the complaint, which is being examined by the authorities and will soon provide a response.

What role does Europe have and why can it "close the "circle"?
A decisive role. With the EU umbrella regulations for the agricultural CAP on the one hand and the European Common Market Organization (CMO) on the other, a uniform framework is being built for the hemp supply chain, from agriculture to trade, for the near future. This clear and harmonized regulation will provide breathing space for European hemp companies and put an end to the patchy interpretations seen among countries, including in our own country. To date, the amendments have passed the committees; the plenary session will be in October.
Europe also plays a key role in the various human uses of hemp. Just recently, EFSA proposed an unrealistic daily CBD intake limit: 2 mg/day was discussed, far from actual usage data and the literature, which reports much higher values ​​(such as 17.5 mg/day). On the ECHA side, we remain vigilant about classifications that could indiscriminately affect extracts and derivatives.
Every well-written line in Brussels strengthens our memories in the chamber, and every well-constructed Italian justification helps Brussels. to bring order. It's the elegant way out even for the most restrictive states: "Europe demands it," and they fall into line.
CSI has organized meetings and conferences for the social partners.
The Senate and the Chamber of Deputies, and through the Honorable Matteo Mauri, Vice President of the Constitutional Affairs Committee, were invited to the hearings. They also filed several appeals, announcing in June 2025 in the Montecitorio Press Room that this appeal is not against the state, but on its side, as it seeks to ascertain the justice and practical legitimacy of its operations. This authentic interpretation will therefore protect more than 3,000 companies and 30,000 seasonal workers, who need nothing more than to put an end to the ambiguity unfortunately generated by this Article 18, which is too often the subject of political polarization and, following the catastrophic news, has led to a particularly repressive attitude on the part of law enforcement.
Payment Systems: Why We Are Conducting a Legal Investigation
Some payment systems have blocked services and sometimes even the private funds of hemp companies. For this reason, legal investigations are being conducted. But these are positive legal actions, not multi-million dollar lawsuits: what hemp companies need is not winning compensation in ten years, but being able to reopen POS terminals tomorrow morning. Specifically, for example, with Nayax (a fintech payment intermediary founded in 2005 in Israel), about twenty members have been suspended. We are therefore taking the PSPs to court to create a pilot case with impeccable documentation and ask the judge to declare it lawful for payment providers to provide services to legitimate hemp operators. We are not looking for "guilty parties" to punish, but rather we would like to establish clear rules that the providers themselves are happy to apply without fear of reputational risks. It's a win-win model: it unlocks the market, protects providers, and protects consumers.

Note to editors: This document may only be published with clear reference to Canapa Sativa Italia (ass.ne) as the authors of the information contained therein.